Clinical Trials
14
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
- Conditions
- Respiratory InsufficiencyPulmonary InflammationRespiratory ComplicationPneumoniaSARS-CoV-2CoronavirusHypoxemic Respiratory FailureCardiac InfarctHypoxic Respiratory FailurePulmonary Edema
- Interventions
- Drug: Pemziviptadil (PB1046)Drug: Low Dose (10 mg) Control
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- PhaseBio Pharmaceuticals Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04433546
- Locations
- 🇺🇸
Baptist Health Research Institute, Jacksonville, Florida, United States
🇺🇸Sarasota Memorial Hospital, Sarasota, Florida, United States
🇺🇸The University of Kansas Medical Center, Kansas City, Kansas, United States
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Pemziviptadil (PB1046) Injection
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- PhaseBio Pharmaceuticals Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03795428
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸University of California - Davis, Sacramento, California, United States
🇺🇸University of Miami - Pulmonary Research Center, Miami, Florida, United States
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Pemziviptadil (PB1046)
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- PhaseBio Pharmaceuticals Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03556020
- Locations
- 🇺🇸
IMC - Diagnostic & Medical Clinic, LLC, Mobile, Alabama, United States
🇺🇸Banner University Medical Center, Tucson, Arizona, United States
🇺🇸University of California, San Diego (UCSD), La Jolla, California, United States
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: PB1046 Subcutaneous Injection
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- PhaseBio Pharmaceuticals Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03315507
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
- Conditions
- Heart Failure
- Interventions
- Drug: PB1046 InjectionDrug: Placebo Injection
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- PhaseBio Pharmaceuticals Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02808585
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Phoenix Medical Research, Peoria, Arizona, United States
🇺🇸Cardiology Associates Research Company, Daytona Beach, Florida, United States
- Prev
- 1
- 2
- 3
- Next